Targeting the CERS4/Rhob/Tim-3 axis through sphingolipid metabolite regulation offers a promising approach to overcome resistance in NSCLC immunotherapy [65] (Fig. 5A). This evidence concerns the gene CERS4 and non-small cell lung carcinoma.